Putting numbers on it

  1. 51 Posts.
    lightbulb Created with Sketch. 1
    Great news, finally.

    I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.

    I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?

    If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.

    Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...

    If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?

    Cheers

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.75
Change
0.005(0.29%)
Mkt cap ! $295.6M
Open High Low Value Volume
$1.70 $1.79 $1.70 $215.1K 124.2K

Buyers (Bids)

No. Vol. Price($)
1 5000 $1.71
 

Sellers (Offers)

Price($) Vol. No.
$1.75 2646 1
View Market Depth
Last trade - 16.10pm 01/07/2025 (20 minute delay) ?
CGS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.